Study on the Development of Kangtai Biologicals in the Context of the COVID-19 Pandemic--Analysis Based on Financial Indicators

According to data from the National Health Commission, as of July 23, 2022, China's full basic immunization rate was 89.7% and booster immunization rate was 71.7%. Among them, the vaccination rate of at least one dose of vaccine for the elderly over 60 years old was 89.6%, the full immunization rate was 84.7%, and the booster immunization rate was 67.3%, and the new crown vaccine has almost reached market saturation. The Novel Coronavirus Pneumonia background, the vaccine industry is facing the new crown vaccine demand instability, the second type of vaccine government supervision is small, social responsibility events occur frequently (Changsheng Biological vaccine counterfeiting events, Beijing Kexing bribery case) and high R & D investment risk, so, based on the Contagious Biological face technology, patents, production capacity and so on a number of barriers, resulting in the decline in performance of the status quo, how to adjust the strategic direction in a timely manner also become a major test. Whether it will change accounting policies to “do high” performance? How about the direction of future development? Is very worth studying. In this paper, we will take Kangtai Bio as a case study, analyze the relevant indexes of its operation ability and development ability, explore the problems in its current development, and put forward relevant suggestions.